BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 33848213)

  • 1. Imaging, clinical, and pathologic findings of Sertoli-leydig cell tumors.
    Chen J; Liu Y; Zhang Y; Wang Y; Chen X; Wang Z
    Sci Prog; 2021; 104(2):368504211009668. PubMed ID: 33848213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DICER1 hotspot mutations in ovarian Sertoli-Leydig cell tumors: a potential association with androgenic effects.
    Kato N; Kusumi T; Kamataki A; Tsunoda R; Fukase M; Kurose A
    Hum Pathol; 2017 Jan; 59():41-47. PubMed ID: 27664536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DICER1-related Sertoli-Leydig cell tumor and gynandroblastoma: Clinical and genetic findings from the International Ovarian and Testicular Stromal Tumor Registry.
    Schultz KAP; Harris AK; Finch M; Dehner LP; Brown JB; Gershenson DM; Young RH; Field A; Yu W; Turner J; Cost NG; Schneider DT; Stewart DR; Frazier AL; Messinger Y; Hill DA
    Gynecol Oncol; 2017 Dec; 147(3):521-527. PubMed ID: 29037807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of the DICER1 hotspot mutation alongside immunohistochemical analysis may provide a better diagnostic measure for ovarian Sertoli-Leydig cell tumors.
    Zhang X; Shen D; Wang Y
    Pathol Res Pract; 2018 Sep; 214(9):1370-1375. PubMed ID: 30072170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DICER1 Mutations Are Consistently Present in Moderately and Poorly Differentiated Sertoli-Leydig Cell Tumors.
    de Kock L; Terzic T; McCluggage WG; Stewart CJR; Shaw P; Foulkes WD; Clarke BA
    Am J Surg Pathol; 2017 Sep; 41(9):1178-1187. PubMed ID: 28654427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Characteristics and Mutation Analyses of Ovarian Sertoli-Leydig Cell Tumors.
    Yuan Z; Huo X; Jiang D; Yu M; Cao D; Wu H; Shen K; Yang J; Zhang Y; Zhou H; Wang Y
    Oncologist; 2020 Sep; 25(9):e1396-e1405. PubMed ID: 32557933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ovarian Sertoli-Leydig cell tumors: DICER1 hotspot mutations and associated clinicopathological features].
    Xiao YX; Zhu XL; Bi R; Tu XY; Cheng YF; Chang B; Yu L; Huang D; Lu YM; Shan L; Yang WT
    Zhonghua Bing Li Xue Za Zhi; 2020 May; 49(5):441-447. PubMed ID: 32392927
    [No Abstract]   [Full Text] [Related]  

  • 8. DICER1 mutations in familial multinodular goiter with and without ovarian Sertoli-Leydig cell tumors.
    Rio Frio T; Bahubeshi A; Kanellopoulou C; Hamel N; Niedziela M; Sabbaghian N; Pouchet C; Gilbert L; O'Brien PK; Serfas K; Broderick P; Houlston RS; Lesueur F; Bonora E; Muljo S; Schimke RN; Bouron-Dal Soglio D; Arseneau J; Schultz KA; Priest JR; Nguyen VH; Harach HR; Livingston DM; Foulkes WD; Tischkowitz M
    JAMA; 2011 Jan; 305(1):68-77. PubMed ID: 21205968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sertoli-Leydig cell tumors of ovary: A case series.
    Xu Q; Zou Y; Zhang XF
    Medicine (Baltimore); 2018 Oct; 97(42):e12865. PubMed ID: 30334998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DICER1 and FOXL2 Mutation Status Correlates With Clinicopathologic Features in Ovarian Sertoli-Leydig Cell Tumors.
    Karnezis AN; Wang Y; Keul J; Tessier-Cloutier B; Magrill J; Kommoss S; Senz J; Yang W; Proctor L; Schmidt D; Clement PB; Gilks CB; Huntsman DG; Kommoss F
    Am J Surg Pathol; 2019 May; 43(5):628-638. PubMed ID: 30986800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Well-differentiated Sertoli-Leydig Cell Tumors (SLCTs) Are Not Associated With DICER1 Pathogenic Variants and Represent a Different Tumor Type to Moderately and Poorly Differentiated SLCTs.
    McCluggage WG; Rivera B; Chong AS; Clarke BA; Schultz KAP; Dehner LP; Tchrakian N; Apellaniz-Ruiz M; Gilks CB; Kommoss F; Stewart CJR; Foulkes WD
    Am J Surg Pathol; 2023 Apr; 47(4):490-496. PubMed ID: 36583307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pediatric Sertoli-Leydig Cell Tumors of the Ovary: An Integrated Study of Clinicopathological Features, Pan-cancer-Targeted Next-generation Sequencing and Chromosomal Microarray Analysis From a Single Institution.
    Yang B; Chour W; Salazar CG; Zamiara P; Schmidt RJ; Raca G; Shillingford N; Zhou S; Warren M; Parham DM; Pawel B; Wang LL
    Am J Surg Pathol; 2024 Feb; 48(2):194-203. PubMed ID: 37946548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DICER1 and FOXL2 mutations in ovarian sex cord-stromal tumours: a GINECO Group study.
    Goulvent T; Ray-Coquard I; Borel S; Haddad V; Devouassoux-Shisheboran M; Vacher-Lavenu MC; Pujade-Laurraine E; Savina A; Maillet D; Gillet G; Treilleux I; Rimokh R
    Histopathology; 2016 Jan; 68(2):279-85. PubMed ID: 26033501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesenteric extraovarian Sertoli-Leydig cell tumor without DICER1 hotspot mutation: a case report.
    Osakabe M; Sato C; Suzuki M; Sugimoto R; Fujita Y; Uesugi N; Ishida K; Itamochi H; Baba T; Sugai T
    Diagn Pathol; 2019 Apr; 14(1):27. PubMed ID: 30935425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review on Sertoli-Leydig Cell Tumours of the Ovary.
    Muscat C; Calleja-Agius J
    Discov Med; 2024 Feb; 36(181):234-247. PubMed ID: 38409829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian Sertoli-Leydig Cell Tumor with Elevated Inhibin B as a Cause of Secondary Amenorrhea in an Adolescent with Germ Line DICER1 Mutation.
    Luke AM; Moroney JW; Snitchler A; Whiteway SL
    J Pediatr Adolesc Gynecol; 2017 Oct; 30(5):598-600. PubMed ID: 28502826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatic tumour testing establishes that bilateral DICER1-associated ovarian Sertoli-Leydig cell tumours represent independent primary neoplasms.
    McCluggage WG; Chong AL; de Kock L; Foulkes WD
    Histopathology; 2020 Aug; 77(2):223-230. PubMed ID: 32333409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct somatic DICER1 hotspot mutations in three metachronous ovarian Sertoli-Leydig cell tumors in a patient with DICER1 syndrome.
    Garcia A; Desrosiers L; Scollon S; Gruner S; Reuther J; Gandhi I; Patil N; Fuller MY; Dai H; Muzny D; Gibbs RA; Bercaw-Pratt JL; Rao SL; Rainusso N; Fisher KE; Lin FY; Plon SE; Parsons DW; Roy A
    Cancer Genet; 2022 Apr; 262-263():53-56. PubMed ID: 35026696
    [No Abstract]   [Full Text] [Related]  

  • 19. Bilateral Ovarian Sertoli-Leydig Cell Tumors Harboring
    Hughes CE; Liang J; Paulson V; Wang H
    Fetal Pediatr Pathol; 2023 Jun; 42(3):472-478. PubMed ID: 36121434
    [No Abstract]   [Full Text] [Related]  

  • 20. Lessons from genomic profiling: towards a molecular-based classification of ovarian Sertoli-Leydig cell tumour.
    Kommoss FKF
    Histopathology; 2024 Mar; 84(4):712-714. PubMed ID: 38114269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.